Products
Pre-made Cinrebafusp Alfa benchmark antibody (Bispecific, anti-ERBB2/HER2;TNFRSF9/CD137 therapeutic antibody, Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;ILA/4-1BB/CDw137 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-780
Pre-made Cinrebafusp Alfa benchmark antibody (Bispecific, anti-ERBB2/HER2;TNFRSF9/CD137 therapeutic antibody, Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;ILA/4-1BB/CDw137 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
cinrebafusp alfa (PRS-343), is a bispecific fusion protein that combines a 4-1BB-targeting Anticalin protein and a HER2-targeting antibody. 4-1BB is an immunoreceptor that powerfully enhances T cell proliferation, survival, and activity.
Cinrebafusp alfa bridges 4-1BB immune cells with HER2-expressing tumor cells, causing the immune cells to cluster around cancerous cells. By combining a 4-1BB-targeting Anticalin proteinwith a HER2-targeting antibody, cinrebafusp alfa focuses 4-1BB activation locally on the tumor, increasing the efficiency of the immune response and reducing systemic toxicity, compared to 4-1BB-targeting antibodies alone.
Cinrebafusp alfa has shown both clinical benefit linked to a 4-1BB mechanism of action, and robust durability, and has been observed to be safe and well-tolerated at all doses and schedules tested.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-780-1mg | 1mg | Inquiry | ||
| GMP-Bios-INN-780-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-780-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-780-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Cinrebafusp Alfa P Alfaiosimilar, Bispecific, Anti-ERBB2/HER2;TNFRSF9 Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;ILA/4-1BB/CDw137 therapeutic antibody |
| INN Name | Cinrebafusp Alfa |
| Target | ERBB2/HER2;TNFRSF9/CD137 |
| Format | Bispecific |
| Derivation | |
| Species Reactivity | |
| CH1 Isotype | |
| VD LC | |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech |
